is phentermine a glp-1 agonist vs GLP-1s: Lower-Cost Weight Loss Options Pharmacology: Weight Loss Medications, Mechanisms

Lack of treatment persistence and treatment nonadherence as barriers to glycaemic control in patients with type 2 diabetes

Davies M, Pieber TR, Hartoft-Nielsen ML, Hansen OKH, Jabbour S, Rosenstock J

doi: 10.1210/en.2009-1272 73 WaserBBeetschenKPellegataNSReubiJC

Like most chronic therapies, GLP-1s are most effective when used consistently, so a formulation that encourages long-term use could have a meaningful impact on patient outcomes.

One patient developed bilateral papillitis, which involves swollen optic nerves that can cause impaired vision, and another had paracentral acute middle maculopathy, which leads to a blind spot in the retina

In the GLP-1 RA group, 190 (1.2%) deaths occurred with a median [IQR] time-to-event of 647 [1881,407] days, whereas the DPP-4i group experienced 175 (1.1%) deaths with a median time-to-event of 549 [2301099] days